Bone marrow transplantation · 2004
Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Клиническое исследованиеСравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Chunxia, Cao Yuzhi, An Mengna, Li Zhihui, Meng Chao, Lan Jingjing, You Haisheng, Chen Siying
Аннотация
OBJECTIVE: To develop and validate a method for therapeutic drug monitoring (TDM) of pyrotinib in human plasma using two-dimensional liquid chromatography (2D-LC) system.
METHOD: The plasma samples were pretreated with acetonitrile for protein precipitation. The mobile phase consisted of two parts: a first-dimensional mobile phase (methanol, acetonitrile, and 65 mmol/L ammonium phosphate in a ratio of 1:3:3, V/V/V) and a second-dimensional mobile phase (acetonitrile, isopropanol, and 10 mmol/L ammonium phosphate in a ratio of 16:7:1, V/V/V). The analysis cycle time was completed within 9.50 min. The method was validated for linearity, recovery, precision, accuracy, and stability.
RESULTS: Pyrotinib demonstrated excellent linearity within the range of 10.10-810.40 ng/mL with regression equation y = 556.4044× + 462.40 (R 2 = 0.9995). The relative recovery rate of plasma samples was stable and reproducible, ranging from 96.82% to 100.12%. The intra-day and inter-day precisions were ≤5.30% and ≤3.80% for pyrotinib concentrations, respectively. Stability tests confirmed that pyrotinib in plasma remained stable under the following conditions: room temperature for 8 h, 4 °C for 48 h, -20 °C for 3 weeks, three freeze-thaw cycles. This method was validated in twenty patients with advanced HER2-positive breast cancer (dose range: 240-400 mg/day) The trough and peak plasma concentrations of pyrotinib ranged from 17.75-92.56 ng/mL and 51.17-232.94 ng/mL, respectively, which demonstrated significant pharmacokinetic heterogeneity.
CONCLUSION: The developed 2D-LC analytical method not only demonstrates good precision, accuracy, recovery, and stability, but also is simple, rapid, feasible, and practical for TDM. It can be used for the concentration monitoring of pyrotinib in clinic, providing more scientific evidence for clinical practice.
METHOD: The plasma samples were pretreated with acetonitrile for protein precipitation. The mobile phase consisted of two parts: a first-dimensional mobile phase (methanol, acetonitrile, and 65 mmol/L ammonium phosphate in a ratio of 1:3:3, V/V/V) and a second-dimensional mobile phase (acetonitrile, isopropanol, and 10 mmol/L ammonium phosphate in a ratio of 16:7:1, V/V/V). The analysis cycle time was completed within 9.50 min. The method was validated for linearity, recovery, precision, accuracy, and stability.
RESULTS: Pyrotinib demonstrated excellent linearity within the range of 10.10-810.40 ng/mL with regression equation y = 556.4044× + 462.40 (R 2 = 0.9995). The relative recovery rate of plasma samples was stable and reproducible, ranging from 96.82% to 100.12%. The intra-day and inter-day precisions were ≤5.30% and ≤3.80% for pyrotinib concentrations, respectively. Stability tests confirmed that pyrotinib in plasma remained stable under the following conditions: room temperature for 8 h, 4 °C for 48 h, -20 °C for 3 weeks, three freeze-thaw cycles. This method was validated in twenty patients with advanced HER2-positive breast cancer (dose range: 240-400 mg/day) The trough and peak plasma concentrations of pyrotinib ranged from 17.75-92.56 ng/mL and 51.17-232.94 ng/mL, respectively, which demonstrated significant pharmacokinetic heterogeneity.
CONCLUSION: The developed 2D-LC analytical method not only demonstrates good precision, accuracy, recovery, and stability, but also is simple, rapid, feasible, and practical for TDM. It can be used for the concentration monitoring of pyrotinib in clinic, providing more scientific evidence for clinical practice.
Предметные рубрики MeSH
Acute DiseaseAdultChronic DiseaseCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHospitalizationHumansImmunosuppressive AgentsIncidenceMaleMethotrexateMiddle AgedMultivariate AnalysisRisk FactorsSecondary PreventionSurvival RateTacrolimusTransplantation, HomologousTreatment Outcome